{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:57:44Z","timestamp":1789934264870,"version":"4.0.1"},"reference-count":86,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T00:00:00Z","timestamp":1699142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Chronic rhinosinusitis (CRS) is an important ENT pathology which affects about 5\u201312% of the general population. The treatment of CRS can be pharmacological (nasal sprays, douches, systemic antibiotics and steroids), surgical (endoscopic sinus surgery) or immunological according to established algorithms. CRS was divided for many years into CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP). New ways of classifying CRS by endotypes (presence of neutrophilia, eosinophilia, fibrosis, glandular hypertrophy and epithelial dysmorphisms) appeared after the most recent understandings of the pathophysiology of the disease. Other classifications divide CRS into primary and secondary forms, localized\/diffuse types and anatomical presentation. A new type of treatment has been administered in the last years, biologics. For the moment, biologics are indicated just in the cases of the patients who have undergone ESS or have contraindications for surgery and have bilateral polyps and meet a minimum of three of the following criteria: the necessity for systemic therapies with oral or parenteral corticosteroids or contraindications to systemic steroids, significant loss of smell or impaired QoL score, comorbid asthma and type 2 inflammation. This article aims to present the most relevant studies which used the three types of biologics (anti-IgE, anti-IL5 and anti-IL4\/IL3) and wishes to increase the awareness of this new type of treatment that can be used in some CRS cases.<\/jats:p>","DOI":"10.3390\/life13112165","type":"journal-article","created":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T07:35:06Z","timestamp":1699169706000},"page":"2165","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Biologics for Chronic Rhinosinusitis\u2014A Modern Option for Therapy"],"prefix":"10.3390","volume":"13","author":[{"given":"Romica","family":"Cergan","sequence":"first","affiliation":[{"name":"Anatomy Department, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7602-9737","authenticated-orcid":false,"given":"Ovidiu Nicolae","family":"Berghi","sequence":"additional","affiliation":[{"name":"Saint Mary Laboratories and Clinics, Carol Davila University of Medicine and Pharmacy, 011013 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1373-2510","authenticated-orcid":false,"given":"Mihai","family":"Dumitru","sequence":"additional","affiliation":[{"name":"ENT Department, Carol Davila University of Medicine and Pharmacy, 050472 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2347-5661","authenticated-orcid":false,"given":"Daniela","family":"Vrinceanu","sequence":"additional","affiliation":[{"name":"ENT Department, Carol Davila University of Medicine and Pharmacy, 050472 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Manole","sequence":"additional","affiliation":[{"name":"ENT Department, Faculty of Medicine, University of Oradea, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crenguta Sorina","family":"Serboiu","sequence":"additional","affiliation":[{"name":"Cellular Biology and Histology Department, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Seah, J.J., Thong, M., and Wang, D.Y. (2023). The Diagnostic and Prognostic Role of Biomarkers in Chronic Rhinosinusitis. Diagnostics, 13.","DOI":"10.3390\/diagnostics13040715"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Czerwaty, K., Piszczatowska, K., Brzost, J., Ludwig, N., Szczepa\u0144ski, M.J., and D\u017caman, K. (2022). Immunological Aspects of Chronic Rhinosinusitis. Diagnostics, 12.","DOI":"10.3390\/diagnostics12102361"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/all.15074","article-title":"Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches","volume":"77","author":"Kato","year":"2021","journal-title":"Allergy"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Tsuda, T., Suzuki, M., Kato, Y., Kidoguchi, M., Kumai, T., Fujieda, S., and Sakashita, M. (Auris Nasus Larynx, 2023). The current findings in eosinophilic chronic rhinosinusitis, Auris Nasus Larynx, in press.","DOI":"10.1016\/j.anl.2023.08.002"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/coa.14001","article-title":"Immunological mechanisms and treatable traits of chronic rhinosinusitis in Asia: A narrative review","volume":"48","author":"Yao","year":"2022","journal-title":"Clin. Otolaryngol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaci.2022.04.013","article-title":"Current insight into treatment of chronic rhinosinusitis: Phenotypes, endotypes, and implications for targeted therapeutics","volume":"150","author":"Chapurin","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamaoto.2020.1453","article-title":"Contemporary Classification of Chronic Rhinosinusitis Beyond Polyps vs No Polyps","volume":"146","author":"Grayson","year":"2020","journal-title":"JAMA Otolaryngol. Neck Surg."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kim, S.-D., and Cho, K.-S. (2023). Treatment Strategy of Uncontrolled Chronic Rhinosinusitis with Nasal Polyps: A Review of Recent Evidence. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24055015"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ha, J.-G., and Cho, H.-J. (2023). Unraveling the Role of Epithelial Cells in the Development of Chronic Rhinosinusitis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241814229"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"109791","DOI":"10.1016\/j.clim.2023.109791","article-title":"The multi-omics single-cell landscape of sinus mucosa in uncontrolled severe chronic rhinosinusitis with nasal polyps","volume":"256","author":"Xu","year":"2023","journal-title":"Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Cui, N., Zhu, X., Zhao, C., Meng, C., Sha, J., and Zhu, D. (2023). A Decade of Pathogenesis Advances in Non-Type 2 Inflammatory Endotypes in Chronic Rhinosinusitis: 2012\u20132022. Int. Arch. Allergy Immunol., 1\u201317.","DOI":"10.1159\/000532067"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaci.2022.10.010","article-title":"Endotypes of chronic rhinosinusitis based on inflammatory and remodeling factors","volume":"151","author":"Wang","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Brzost, J., Czerwaty, K., D\u017caman, K., Ludwig, N., Piszczatowska, K., and Szczepa\u0144ski, M.J. (2022). Perspectives in Therapy of Chronic Rhinosinusitis. Diagnostics, 12.","DOI":"10.3390\/diagnostics12102301"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4193\/Rhin20.601","article-title":"Executive Summary of EPOS 2020 Including Integrated Care Pathways","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinol. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4193\/Rhin17.240","article-title":"Multivariate analysis of inflammatory endo-types in recurrent nasal polyposis in a Chinese population","volume":"56","author":"Wei","year":"2018","journal-title":"Rhinology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/cea.12287","article-title":"Local increase in IgE and class switch recombination to IgE in nasal polyps in chronic rhinosinusitis","volume":"44","author":"Baba","year":"2014","journal-title":"Clin. Exp. Allergy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1365-2222.2005.02316.x","article-title":"Nasal biomarker profiles in acute and chronic rhinosinusitis","volume":"35","author":"Riechelmann","year":"2005","journal-title":"Clin. Exp. Allergy"},{"key":"ref_18","first-page":"CD013513","article-title":"Biologics for chronic rhinosinusitis","volume":"2021","author":"Chong","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kobayashi, Y., Kanda, A., Van Bui, D., Yun, Y., Nguyen, L.M., Chu, H.H., Mitani, A., Suzuki, K., Asako, M., and Iwai, H. (2021). Omalizumab Restores Response to Corticosteroids in Patients with Eosinophilic Chronic Rhinosinusitis and Severe Asthma. Biomedicines, 9.","DOI":"10.3390\/biomedicines9070787"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102080","DOI":"10.1016\/j.pupt.2021.102080","article-title":"Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps","volume":"71","author":"Zhu","year":"2021","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhino09.144","article-title":"A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis","volume":"48","author":"Pinto","year":"2010","journal-title":"Rhinol. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.anai.2013.01.024","article-title":"Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma","volume":"110","author":"Tajiri","year":"2013","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/19458924211030486","article-title":"Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis","volume":"36","author":"Damask","year":"2021","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_26","first-page":"435","article-title":"Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps","volume":"60","author":"Haxel","year":"2022","journal-title":"Rhinol. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4193\/Rhin17.139","article-title":"Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study","volume":"56","author":"Bidder","year":"2018","journal-title":"Rhinol. J."},{"key":"ref_28","first-page":"516","article-title":"Effects of Omalizumab Treatment in Patients with Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study","volume":"35","year":"2020","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100670","DOI":"10.1016\/j.waojou.2022.100670","article-title":"Omalizumab is effective in nasal polyposis with or without asthma, a real-life study","volume":"15","author":"Tat","year":"2022","journal-title":"World Allergy Organ. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100702","DOI":"10.1016\/j.waojou.2022.100702","article-title":"Clinical effectiveness and potential predictability of omalizumab in patients with difficult-to-treat chronic rhinosinusitis with nasal polyps and asthma based on the noninvasive markers\u2013A real-life prospective study","volume":"15","author":"Zheng","year":"2022","journal-title":"World Allergy Organ. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/lary.26391","article-title":"Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis","volume":"127","author":"DeConde","year":"2017","journal-title":"Laryngoscope"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/all.14902","article-title":"Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis","volume":"77","author":"Canonica","year":"2021","journal-title":"Allergy"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/cea.13852","article-title":"Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial","volume":"51","author":"Tversky","year":"2021","journal-title":"Clin. Exp. Allergy"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/19458924211009429","article-title":"A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients with Eosinophilic Chronic Rhinosinusitis","volume":"35","author":"Takabayashi","year":"2021","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101965","DOI":"10.1016\/j.pupt.2020.101965","article-title":"Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps","volume":"64","author":"Matsuno","year":"2020","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/1945892420978351","article-title":"Effect of Benralizumab in Patients with Severe Eosinophilic Asthma and Chronic Rhinosinusitis With Nasal Polyps: A Case Series","volume":"35","author":"Chitguppi","year":"2020","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2058738420950851","DOI":"10.1177\/2058738420950851","article-title":"Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma","volume":"34","author":"Lombardo","year":"2020","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","article-title":"Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study","volume":"9","author":"Nolasco","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.imlet.2022.06.009","article-title":"Benralizumab reduces eosinophils and inflammatory markers in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: A pilot real-life study","volume":"248","author":"Cavaliere","year":"2022","journal-title":"Immunol. Lett."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Santomasi, C., Buonamico, E., Dragonieri, S., Iannuzzi, L., Portacci, A., Quaranta, N., and Carpagnano, G.E. (2023). Effects of benralizumab in a population of patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: A real life study. Acta Biomed., 94.","DOI":"10.1183\/13993003.congress-2022.575"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/all.15434","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In-depth sinus surgery analysis","volume":"78","author":"Fokkens","year":"2022","journal-title":"Allergy"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Gallo, S., Castelnuovo, P., Spirito, L., Feduzi, M., Seccia, V., Visca, D., Spanevello, A., Statuti, E., Latorre, M., and Montuori, C. (2022). Mepolizumab Improves Outcomes of Chronic Rhinosinusitis with Nasal Polyps in Severe Asthmatic Patients: A Multicentric Real-Life Study. J. Pers. Med., 12.","DOI":"10.3390\/jpm12081304"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"17534666211009398","DOI":"10.1177\/17534666211009398","article-title":"Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: A 12-month real-life study","volume":"15","author":"Detoraki","year":"2021","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Dom\u00ednguez-Sosa, M.S., Cabrera-Ram\u00edrez, M.S., Marrero-Ramos, M.d.C., D\u00e1vila-Quintana, D., Cabrera-L\u00f3pez, C., Carrillo-D\u00edaz, T., and del Rosario, J.J.B. (2023). Real-Life Effectiveness of Mepolizumab in Refractory Chronic Rhinosinusitis with Nasal Polyps. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020485"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti\u2013IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/all.13685","article-title":"Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis","volume":"74","author":"Jonstam","year":"2018","journal-title":"Allergy"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.jaip.2019.03.023","article-title":"Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma","volume":"7","author":"Bachert","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/lary.29911","article-title":"Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds","volume":"132","author":"Chuang","year":"2021","journal-title":"Laryngoscope"},{"key":"ref_55","first-page":"10","article-title":"Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP","volume":"58","author":"Bachert","year":"2019","journal-title":"Rhinol. J."},{"key":"ref_56","first-page":"E1770","article-title":"The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan","volume":"131","author":"Fujieda","year":"2020","journal-title":"Laryngoscope"},{"key":"ref_57","first-page":"301","article-title":"Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP","volume":"59","author":"Desrosiers","year":"2021","journal-title":"Rhinol. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/alr.22780","article-title":"Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"11","author":"Hopkins","year":"2021","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1111\/all.15222","article-title":"Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies","volume":"77","author":"Lee","year":"2022","journal-title":"Allergy"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaip.2021.09.037","article-title":"Olfactory Outcomes with Dupilumab in Chronic Rhinosinusitis with Nasal Polyps","volume":"10","author":"Mullol","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.anai.2022.11.006","article-title":"Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps","volume":"130","author":"Berger","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.anai.2021.01.012","article-title":"Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma","volume":"126","author":"Laidlaw","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaip.2019.07.016","article-title":"Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis","volume":"8","author":"Maspero","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s00405-022-07679-y","article-title":"Dupilumab (Dupixent\u00ae) tends to be an effective therapy for uncontrolled severe chronic rhinosinusitis with nasal polyps: Real data of a single-centered, retrospective single-arm longitudinal study from a university hospital in Germany","volume":"280","author":"Jansen","year":"2022","journal-title":"Eur. Arch. Oto-Rhino-Laryngol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"De Corso, E., Settimi, S., Montuori, C., Corb\u00f2, M., Passali, G.C., Porru, D.P., Verde, S.L., Spanu, C., Penazzi, D., and Di Bella, G.A. (2022). Effectiveness of Dupilumab in the Treatment of Patients with Severe Uncontrolled CRSwNP: A \u201cReal-Life\u201d Observational Study in the First Year of Treatment. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102684"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ottaviano, G., Saccardo, T., Roccuzzo, G., Bernardi, R., Di Chicco, A., Pendolino, A.L., Scarpa, B., Mairani, E., and Nicolai, P. (2022). Effectiveness of Dupilumab in the Treatment of Patients with Uncontrolled Severe CRSwNP: A \u201cReal-Life\u201d Observational Study in Na\u00efve and Post-Surgical Patients. J. Pers. Med., 12.","DOI":"10.3390\/jpm12091526"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Galletti, C., Barbieri, M.A., Ciodaro, F., Freni, F., Galletti, F., Spina, E., and Galletti, B. (2023). Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care. Pharmaceuticals, 16.","DOI":"10.3390\/ph16040630"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"100780","DOI":"10.1016\/j.waojou.2023.100780","article-title":"Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy","volume":"16","author":"Albrecht","year":"2023","journal-title":"World Allergy Organ. J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"37","DOI":"10.18176\/jiaci.0812","article-title":"Smell improvement by anti-IgE and anti-IL 5 biologics in patients with CRSwNP and severe asthma. A real life study","volume":"33","author":"Barroso","year":"2022","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1159\/000514262","article-title":"Real-Life Experience of Monoclonal Antibody Treatments in Chronic Rhinosinusitis with Nasal Polyposis","volume":"182","author":"Meier","year":"2021","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/1744666X.2023.2218617","article-title":"Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making","volume":"19","author":"Otten","year":"2023","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"100746","DOI":"10.1016\/j.waojou.2023.100746","article-title":"A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics","volume":"16","author":"Stergioudi","year":"2023","journal-title":"World Allergy Organ. J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jaip.2022.02.034","article-title":"Comparison of Different Biologics for Treating Chronic Rhinosinusitis with Nasal Polyps: A Network Analysis","volume":"10","author":"Cai","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/alr.23059","article-title":"A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis","volume":"13","author":"Miglani","year":"2022","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e12269","DOI":"10.1002\/clt2.12269","article-title":"Comparative short-term efficacy of endoscopic sinus surgery and biological therapies in chronic rhinosinusitis with nasal polyps: A network meta-analysis","volume":"13","author":"Chen","year":"2023","journal-title":"Clin. Transl. Allergy"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Maza-Solano, J., Calvo-Henr\u00edquez, C., Alobid, I., \u00c1lvarez-Cendrero, M., Palomares, \u00d3., Moreno-Luna, R., Santos-Perez, J., Gonz\u00e1lez-Garc\u00eda, J., and S\u00e1nchez-G\u00f3mez, S. (2022). Nasal Symptoms in Asthmatic Patients under Treatment with Anti-IL-5 Monoclonal Antibodies. A Real-Life Cohort Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11237056"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.anai.2022.04.004","article-title":"Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps","volume":"129","author":"Borish","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.anorl.2010.04.004","article-title":"Coblation turbinate reduction in childhood allergic rhinitis","volume":"127","author":"Soufflet","year":"2010","journal-title":"Eur. Ann. Otorhinolaryngol. Head Neck Dis."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Abdullah, B., and Singh, S. (2021). Surgical Interventions for Inferior Turbinate Hypertrophy: A Comprehensive Review of Current Techniques and Technologies. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18073441"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"42","DOI":"10.14639\/0392-100X-N1984","article-title":"Surgical management of chronic rhinosinusitis with nasal polyps under local anaesthesia: Indications and results","volume":"43","author":"Mimari","year":"2023","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40463-021-00493-2","article-title":"Canadian Rhinology Working Group consensus statement: Biologic therapies for chronic rhinosinusitis","volume":"50","author":"Thamboo","year":"2021","journal-title":"J. Otolaryngol. Head Neck Surg."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Rizzi, A., Gammeri, L., Cordiano, R., Valentini, M., Centrone, M., Marrone, S., Inchingolo, R., Lohmeyer, F.M., Cavaliere, C., and Ria, F. (2023). Therapeutic Strategies to Prevent the Recurrence of Nasal Polyps after Surgical Treatment: An Update and In Vitro Study on Growth Inhibition of Fibroblasts. J. Clin. Med., 12.","DOI":"10.3390\/jcm12082841"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaci.2022.02.029","article-title":"Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps","volume":"150","author":"Bai","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"75","DOI":"10.14639\/0392-100X-N1699","article-title":"Chronic rhinosinusitis with nasal polyps: How to identify eligible patients for biologics in clinical practice","volume":"42","author":"Gelardi","year":"2022","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jaip.2022.03.002","article-title":"Chronic Rhinosinusitis with Nasal Polyps: Quality of Life in the Biologics Era","volume":"10","author":"Mullol","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_86","first-page":"194","article-title":"EPOS\/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinol. J."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/11\/2165\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:17:47Z","timestamp":1760131067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/11\/2165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,5]]},"references-count":86,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["life13112165"],"URL":"https:\/\/doi.org\/10.3390\/life13112165","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,5]]}}}